Screener
Travere Therapeutics, Inc. TVTX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Selling, general and administrative | 80,254 | 60,413 |
| Royalty expense | 24,816 | 12,425 |
| Total operating expenses | 164,114 | 124,406 |
| Operating loss | (36,915) | (42,674) |
| Other income, net: | ||
| Interest income | 2,584 | 3,795 |
| Interest expense | (2,300) | (2,857) |
| Other (expense) income, net | (91) | 549 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s operating income?
- Travere Therapeutics, Inc. (TVTX) reported operating income of -$36.92M in Q1 2026.
- How has Travere Therapeutics, Inc.'s operating income changed year-over-year?
- Travere Therapeutics, Inc.'s operating income increased by 13.5% year-over-year, from -$42.67M to -$36.92M.
- What is the long-term trend for Travere Therapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s operating income has grown at a -25.1% compound annual growth rate (CAGR), from -$199.43M to -$62.82M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Travere Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude